-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical (01276): HRS5580 for injection obtained approval notice for drug clinical trials

Zhitongcaijing·07/29/2026 14:09:07
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for injectable HRS5580, which will conduct clinical trials in the near future.

HRS5580 for injection is a selective neurokinpeptide-1 (NK-1) receptor antagonist. It blocks P substance binding to NK-1 receptors through high affinity and exerts a strong antiemetic effect. This variety has differentiated advantages such as high solubility, good safety, and long-term effect. According to inquiries, the same target drugs that have been marketed globally, such as Heron's aripitane injection emulsion (APONVIE®), are all short-acting NK-1 antagonists, and no long-term formulation has yet been approved. Up to now, the total R&D investment for HRS5580 related projects is about 57.7 million yuan (unaudited).